secwatch.observer — SEC 8-K summary
======================================

Issuer:     Synergy Empire Ltd (—)
CIK:        0001766267
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001641172-25-002536
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 3.02, 5.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synergy Empire acquires Meluha Therapeutics for $2.3M in preferred stock; shifts to stem cell medicine
--------------------------------------------------------------------------------

- Acquired 100% of Meluha Therapeutics on March 28, 2025, for 10M Series A preferred shares valued at $2.3M.
- Company pivots from F&B consultancy to biopharmaceutical manufacturing of stem cell therapies.
- Meluha directors Ramesh A/L Saravanamuthu and Abdul Jalil bin Jidon received 3.36M and 3.19M preferred shares respectively.
- No financial details of Meluha (revenue/profit) disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766267/000164117225002536/0001641172-25-002536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766267/000164117225002536/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-002536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer